Alisertib (Standard)

CAT:
804-HY-10971R-01
Size:
5 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Alisertib (Standard) - image 1

Alisertib (Standard)

  • Description:

    Alisertib (Standard) is the analytical standard of Alisertib. This product is intended for research and analytical applications. Alisertib (MLN 8237) is an orally active and selective Aurora A kinase inhibitor (IC50=1.2 nM), which binds to Aurora A kinase resulting in mitotic spindle abnormalities, mitotic accumulation. Alisertib (MLN 8237) induces apoptosis and autophagy through targeting the AKT/mTOR/AMPK/p38 pathway in leukemic cells. Antitumor activity[1][2][3].
  • UNSPSC:

    12352100
  • Target:

    Apoptosis; Aurora Kinase; Autophagy; Reference Standards
  • Related Pathways:

    Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; Others
  • Field of Research:

    Cancer
  • Smiles:

    O=C(C1=CC=C(C=C1OC)NC2=NC=C3CN=C(C4=CC(Cl)=CC=C4C3=N2)C5=C(C=CC=C5F)OC)O
  • Molecular Formula:

    C27H20ClFN4O4
  • Molecular Weight:

    518.92
  • References & Citations:

    [1]Güllü G, et al. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma Blood June 24, 2010 vol. 115 no. 25 5202-5213.|[2]Sloane DA, et al. Drug-Resistant Aurora A Mutants for Cellular Target Validation of the Small Molecule Kinase Inhibitors MLN8054 and MLN8237 ACS Chem. Biol., 2010, 5 (6), pp 563-576.|[3]Bavetsias V, et al. Aurora Kinase Inhibitors: Current Status and Outlook. Front Oncol. 2015 Dec 21;5:278.|[4]Manfredi MG, et al. Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays.Clin Cancer Res. 2011 Dec 15;17 (24) :7614-7624.
  • Shipping Conditions:

    Room temperature
  • Scientific Category:

    Reference Standards
  • CAS Number:

    [1028486-01-2]